Recent Company News

• 09:05 AM ET Oct 05, 2026
  

  Capricor Therapeutics presents HOPE-3 OLE data on upper limb function in DMD at 2026 World Muscle Society Congress ($8.95, 0.00)

• 03:09 PM ET Oct 02, 2026
  

  Lilly announces Jaypirca (pirtobrutinib) receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL ($1147.33, -2.52)

• 06:29 AM ET Sep 28, 2026
  

  NMPA approves Innovent Biologics' Jaypirca for CLL/SLL across all lines of therapy (HK$96.15, 0.00)

• 02:09 PM ET Sep 25, 2026
  

  FDA approves Roche's Gazyva for the treatment of Idiopathic nephrotic syndrome in patients 2+ (CHF 360.30, 0.00)

• 02:02 PM ET Aug 31, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 24-Aug

• 09:29 AM ET Aug 24, 2026
  

  Follow-up: Capricor Therapeutics announces extension of PDUFA date for deramiocel BLA, until 22-Nov ($6.29, 0.00)

• 07:28 AM ET Aug 24, 2026
  

  REGENXBIO announces FDA has placed clinical hold on RGX-121 for MPS II (7:05ET) ($10.72, 0.00)

• 05:07 PM ET Aug 22, 2026
  

  FDA grants orphan drug designation to pirtobrutinib for ITP ($1255.40, 0.00)

• 11:03 PM ET Aug 05, 2026
  

  Nippon Shinyaku reports Q1 net income attributable ¥10.11B vs FactSet ¥6.80B [4 est, ¥4.30-8.18B] (¥3522.0000, +49)

• 10:42 AM ET Aug 05, 2026
  

  Epilepsia Open publishes results of post hoc data analysis of FINTEPLA (fenfluramine) in patients with Lennox-Gastaut syndrome (€230.10, +6.80)